The Importance of Personalized Medicine in Chronic Myeloid Leukemia Management: A Narrative Review Publisher



Zaker E^{1, 2} ; Nouri N^{1, 2} ; Sorkhizadeh S³ ; Ghasemirad H⁴ ; Hajijafari AH⁵ ; Zare F^{6, 7}
Source: Egyptian Journal of Medical Human Genetics Published:2023

Abstract

Background: Tyrosine kinase inhibitors (TKIs) are prescribed as a targeted therapy to treat chronic myeloid leukemia patients. A challenge in clinical practice is that despite excellent efficacy and improved clinical response levels acquired by imatinib, a number of patients receive TKI therapy but have a poor primary response, develop a drug resistance, or relapse after initial success. This inter-individual difference into response has increased the concern in investigating the pharmacogenetics of cancer drugs. This review discusses the influence of various factors, such as BCR-ABL point mutation, efflux and influx transporters, and others, on targeted drug response in CML. Additionally, we focus on how patients can overcome these issues. © 2023, The Author(s).